JPRN-UMIN000007372RecruitingPhase 2
PhaseII study of Combination FOLFIRI with Cetuximab in patients with advanced/metastatic colorectal cancer previously received oxaliplatin-based chemoterapy. - PhaseII study of Combination FOLFIRI with Cetuximab in patients with advanced/metastatic colorectal cancer previously received oxaliplatin-based chemoterapy.
Kurume University School of medicine, Department of Surgery0 sites30 target enrollmentStarted: February 24, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1)Severe bone marrow suppression (2)Wattery diarrhea (3)Severe infectious disease (4)Massive pleural effusion or ascites (5)Comorbidity or history of heart failure (6)Comorbidity or history of interstitial lung disease or pulmonary fibrosis (7)Paralytic or mechanical bowel obstruction (8)Jaundice (9)Patients who is receiving Atazanavir Sulfate (10)History of severe allergy (11)Pregnant or lactating women or women of childbearing potential (12)Severe comorbidity (uncontrolable diabetes, hypertension, hypercarcemia etc) (13)Symptomatic brain metastasis (14)Simultaneous or metachronous double cancers (15)Any other cases who are regarded as inadequate for study enrollment by the investigator
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / Vadvanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / VEUCTR2018-003778-29-ITIstituto Nazionale Tumori G. Pascale34
Completed
Phase 2
Phase II study of FOLFIRI + cetuximab as induction chemotherapy followed by FOLFIRI + bevacizumab based on early tumor shrinkage in chemotherapy-naive patients with RAS wild-type colorectal cancerColorectal cancerJPRN-UMIN000023026Department of Clinical Oncology, St. Marianna University School of Medicine54
Active, not recruiting
Not Applicable
Study of the effectiveness of a treatment that involves the combination chemotherapy regimen of 5-fluorouracil+Oxaliplatin+irinotecan (Folfoxiri)to a biologic antineoplatic target therapy Erbitux on the end result from treatment with Erbitux or another biologic agent bevacizumab in the patients unresectable that showing the expression of wild-type KRAS oncogeneRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTSMedDRA version: 14.1Level: LLTClassification code 10050035Term: Metastatic colon cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000840-70-ITG.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
Completed
Phase 2
Phase IIstudy of biweekly FOLFIRI+cetuximab treatment for unresectable KRAS-wild type colorectal cancerunresectable colorectal cancerJPRN-UMIN000011363Dept of Surgical Oncology Osaka City University Graduate School of Medicine20
Completed
Phase 2
Cetuximab Standard or Dose Escalation in First Line Colorectal CancerColorectal CancerNCT01251536Universitaire Ziekenhuizen KU Leuven108